Iqymune (Human Normal Immunoglobulin)

Iqymune, an intravenous immunoglobulin, is employed in several immunodeficiency and immune‑mediated disease pathways.

• Primary immunodeficiency diseases: restores circulating IgG levels, reducing the frequency and severity of infections.
• Secondary immunodeficiency (e.g., chemotherapy, HIV): supplements depleted antibodies to help prevent opportunistic infections.
• Idiopathic thrombocytopenic purpura: modulates immune response to increase platelet counts and reduce bleeding risk.
• Chronic inflammatory demyelinating polyneuropathy: provides immunomodulation that can improve nerve function and reduce relapse rates.

• Human Normal Immunoglobulin consists of pooled IgG antibodies derived from healthy donors. After intravenous infusion, the antibodies distribute throughout the vascular and extravascular compartments, where they bind and neutralize pathogens, opsonize microbes for phagocytosis, and modulate complement activation. The preparation also interacts with Fc receptors on immune cells, dampening auto‑reactive responses and providing immunoregulatory effects that help restore immune balance in deficient or dysregulated states.

Intravenous immunoglobulin therapy can be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Headache: mild to moderate pain often occurring during or shortly after infusion.
• Fever and chills: transient rise in body temperature and shaking sensations.
• Nausea or vomiting: gastrointestinal discomfort during administration.
• Fatigue: feeling of tiredness that may last several hours post‑infusion.
• Infusion‑related reactions: erythema, flushing, or mild hypotension.

Serious or Rare Side Effects

• Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
• Thromboembolic events: blood clots that can affect veins or arteries.
• Acute renal failure: sudden loss of kidney function, especially in high‑risk patients.
• Aseptic meningitis: inflammation of the meninges without infection.
• Hemolysis: destruction of red blood cells leading to anemia.

Before initiating Iqymune therapy, several safety considerations should be reviewed to minimize risks.

• Assess renal function: monitor serum creatinine and urine output before and during treatment.
• Screen for IgA deficiency: patients with anti‑IgA antibodies are at increased risk of anaphylaxis.
• Evaluate thrombotic risk: consider history of cardiovascular disease or hypercoagulability.
• Use caution in pregnancy: limited safety data, weigh potential benefits against unknown risks.
• Monitor for aseptic meningitis: observe for severe headache, neck stiffness, or photophobia.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Intravenous immunoglobulin may interact with other medicines, altering their effectiveness or safety profile.

Major Interactions (Avoid)

• Live vaccines: immunoglobulin can neutralize vaccine viruses, reducing efficacy; avoid concurrent administration.
• High‑IgA blood products: may trigger severe anaphylactic reactions in IgA‑deficient patients.

Moderate Interactions (Monitor Closely)

• Inactivated vaccines: possible reduced immune response; schedule vaccination appropriately.
• Anticoagulants (e.g., warfarin): IVIG can affect coagulation parameters, requiring closer INR monitoring.
• Diuretics and nephrotoxic drugs: increased risk of renal impairment; monitor kidney function closely.